<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01038804</url>
  </required_header>
  <id_info>
    <org_study_id>155-CL-036</org_study_id>
    <secondary_id>2009-012439-14</secondary_id>
    <nct_id>NCT01038804</nct_id>
  </id_info>
  <brief_title>A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate survival, response rate, safety and tolerability of
      YM155 given in combination with docetaxel as first-line treatment in subjects with human
      epidermal growth factor 2 non-overexpressing (HER2 negative) metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an outpatient study. All subjects enrolled in this study will receive a combined
      regimen of YM155 and docetaxel or docetaxel alone given during 21 day cycles. Each subject
      will be assessed at the end of each cycle to determine if the subject can continue to the
      next cycle. Each subject assigned to receive YM155 in combination with docetaxel will be
      eligible to continue receiving the combination regimen in this study until one of the
      discontinuation criteria is met.

      If a subject discontinues treatment with at least stable disease (SD) that subject will
      complete follow-up visits every 12 weeks for 2 years or until initiating another systemic
      anti-breast cancer treatment, exhibiting progressive disease (PD), or death.

      Each subject will be contacted by the study site every 12 weeks for survival following the
      End of Treatment Visit. The contacts will continue until death or for no more than 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>At the time of progression or death or at 2 year follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (proportion of subjects with complete response or partial response)</measure>
    <time_frame>At the time of progression or death or at 2 year follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At the time of death or at 2 year follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>At the time of progression or at 2 year follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>At the time of progression or death or at 2 year follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>At the time of response or at 2 year follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by recording of adverse events, physical examinations, vital signs, laboratory assessments and electrocardiograms (ECGs)</measure>
    <time_frame>Up to 30 days after last subject discontinues treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A. YM155 plus docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B. docetaxel alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM155</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>A. YM155 plus docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>A. YM155 plus docetaxel</arm_group_label>
    <arm_group_label>B. docetaxel alone</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically- or cytologically-proven adenocarcinoma of the breast that is HER2
             negative. Subjects with hormone receptor positive or negative status are eligible.
             Additionally, subjects with triple negative status (meaning estrogen receptor
             negative, progesterone receptor negative and HER2 negative) are eligible

          -  No prior chemotherapy regimen for metastatic breast cancer

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 at the Baseline Visit

          -  The subject's life expectancy is estimated to be &gt; 12 weeks at the Baseline Visit

          -  The subject must be non-pregnant and non-lactating. All sexually active subjects of
             childbearing potential must agree to use an adequate method of contraception
             throughout the study period

        Exclusion Criteria:

          -  Hypersensitivity to docetaxel or polysorbate 80

          -  Neuropathy ≥ Grade 2 at the Baseline Visit

          -  Known brain or leptomeningeal metastasis as assessed through medical history review
             and physical examination

          -  The subject has known Human Immunodeficiency Virus (HIV), Hepatitis B surface Antigen
             or hepatitis C antibody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sr. Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <overall_official>
    <last_name>United Kingdom Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Bournemouth Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Poland Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centrum Onkologii-Instytut im.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ireland Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Vincent's University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Germany Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Luisenkrankenhaus Duesseldorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Czech Republic Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomayer Faculty Hosptial L.G.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Belgium Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Jules Bordet - Medical Oncology and Translational Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kenmar Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Cancer Research Group</name>
      <address>
        <city>Pleasant Hill</city>
        <state>California</state>
        <zip>94523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Cancer Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Cancer Institute Foundation c/o Montana Cancer Specialists</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Oncology Specialists, PA</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet - Medical Oncology and Translational Research</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi - Site Notre Dame</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint-Augustinus GZA Ziekenhuizen</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Kralovske Vinohrady</name>
      <address>
        <city>Prague 10</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Na Bulovce</name>
      <address>
        <city>Prague</city>
        <zip>180 81</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-onkologische Praxis</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik des Universitätsklinikums Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Schleswig</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der Borromaeerinnen</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology</name>
      <address>
        <city>Dublin</city>
        <zip>9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii-Instytut im.</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Therapeutic and Prophylactic Institution Chelyabinsk Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare institution &quot;Kursk Regional Oncology Dispensary&quot; of Kursk Region Healthcare committee GUZ &quot;KOOD&quot;</name>
      <address>
        <city>Kursk</city>
        <zip>305035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of Russian Academy of Medical Sciences Russian Oncology Research Centre</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pyatigorsk Oncology Dispensary</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357500</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific-Research Institute of Oncology named after Petrov</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>189646</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Medical University named after Pavlov</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution &quot;Samara Regional Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Samara</city>
        <zip>443031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tula Regional Dispensary</name>
      <address>
        <city>Tula</city>
        <zip>300053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2009</study_first_posted>
  <disposition_first_submitted>July 11, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>July 11, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 15, 2013</disposition_first_posted>
  <last_update_submitted>September 12, 2013</last_update_submitted>
  <last_update_submitted_qc>September 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>HER2 Negative</keyword>
  <keyword>YM155</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

